Poisoning of Mitochondrial Topoisomerase I by Lamellarin D

Lamellarin D (Lam-D) is a hexacyclic pyrole alkaloid isolated from marine invertebrates, whose biologic properties have been attributed to mitochondrial targeting. Mitochondria contain their own DNA (mtDNA), and the only specific mitochondrial topoisomerase in vertebrates is mitochondrial topoisomerase I (Top1mt). Here, we show that Top1mt is a direct mitochondrial target of Lam-D. In vitro Lam-D traps Top1mt and induces Top1mt cleavage complexes (Top1mtcc). Using single-molecule analyses, we also show that Lam-D slows down supercoil relaxation of Top1mt and strongly inhibits Top1mt religation in contrast to the inefficacy of camptothecin on Top1mt. In living cells, we show that Lam-D accumulates rapidly inside mitochondria, induces cellular Top1mtcc, and leads to mtDNA damage. This study provides evidence that Top1mt is a direct mitochondrial target of Lam-D and suggests that developing Top1mt inhibitors represents a novel strategy for targeting mitochondrial DNA.

[1]  Justin J. Wilson,et al.  Targeting mitochondrial DNA with a platinum-based anticancer agent. , 2013, Chemistry & biology.

[2]  Morten O. Christensen,et al.  Negative regulation of mitochondrial transcription by mitochondrial topoisomerase I , 2013, Nucleic acids research.

[3]  J. Neuzil,et al.  Classification of mitocans, anti-cancer drugs acting on mitochondria. , 2013, Mitochondrion.

[4]  S. Kelley,et al.  Targeted delivery of doxorubicin to mitochondria. , 2013, ACS chemical biology.

[5]  A. Szewczyk,et al.  Mitochondria as a pharmacological target: Magnum overview , 2013, IUBMB life.

[6]  Y. Pommier Drugging topoisomerases: lessons and challenges. , 2013, ACS chemical biology.

[7]  Y. Pommier,et al.  A kinetic clutch governs religation by type IB topoisomerases and determines camptothecin sensitivity , 2012, Proceedings of the National Academy of Sciences.

[8]  S. Dhar,et al.  Engineering of blended nanoparticle platform for delivery of mitochondria-acting therapeutics , 2012, Proceedings of the National Academy of Sciences.

[9]  G. Brockhoff,et al.  Targeting drugs to mitochondria. , 2012, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[10]  Y. Pommier,et al.  Mitochondrial Topoisomerase I is Critical for Mitochondrial Integrity and Cellular Energy Metabolism , 2012, PloS one.

[11]  Raquel Herrador,et al.  Topoisomerase I poisoning results in PARP-mediated replication fork reversal , 2012, Nature Structural &Molecular Biology.

[12]  Yves Pommier,et al.  Interfacial inhibitors: targeting macromolecular complexes , 2012, Nature Reviews Drug Discovery.

[13]  J. Edwards,et al.  Chronically elevated glucose compromises myocardial mitochondrial DNA integrity by alteration of mitochondrial topoisomerase function. , 2011, American journal of physiology. Cell physiology.

[14]  Yuxin Cui,et al.  Total synthesis of lamellarins D, H, and R and ningalin B. , 2011, Organic letters.

[15]  Y. Pommier,et al.  Role of tyrosyl-DNA phosphodiesterase (TDP1) in mitochondria , 2010, Proceedings of the National Academy of Sciences.

[16]  N. Osheroff,et al.  The geometry of DNA supercoils modulates the DNA cleavage activity of human topoisomerase I , 2010, Nucleic acids research.

[17]  Joel N. Meyer,et al.  The QPCR assay for analysis of mitochondrial DNA damage, repair, and relative copy number. , 2010, Methods.

[18]  Yves Pommier,et al.  DNA topoisomerases and their poisoning by anticancer and antibacterial drugs. , 2010, Chemistry & biology.

[19]  C. Chi,et al.  Mitochondrial DNA Content as a Potential Marker to Predict Response to Anthracycline in Breast Cancer Patients , 2010, The breast journal.

[20]  Christian Bailly,et al.  Inhibition of mitochondrial respiration mediates apoptosis induced by the anti-tumoral alkaloid lamellarin D , 2010, Apoptosis.

[21]  Christian Bailly,et al.  Essential role of mitochondria in apoptosis of cancer cells induced by the marine alkaloid Lamellarin D , 2009, Molecular Cancer Therapeutics.

[22]  S. Kelley,et al.  Targeting Mitochondria with Organelle‐Specific Compounds: Strategies and Applications , 2009, Chembiochem : a European journal of chemical biology.

[23]  Yidong Bai,et al.  Implications of mitochondrial DNA mutations and mitochondrial dysfunction in tumorigenesis , 2009, Cell Research.

[24]  Y. Pommier,et al.  DNA cleavage assay for the identification of topoisomerase I inhibitors , 2008, Nature Protocols.

[25]  Y. Pommier,et al.  Mitochondrial topoisomerase I sites in the regulatory D-loop region of mitochondrial DNA. , 2008, Biochemistry.

[26]  F. Albericio,et al.  Recent advances in lamellarin alkaloids: isolation, synthesis and activity. , 2008, Anti-cancer agents in medicinal chemistry.

[27]  T. Mizumachi,et al.  Induction of acquired resistance to antiestrogen by reversible mitochondrial DNA depletion in breast cancer cell line , 2007, International journal of cancer.

[28]  Y. Pommier,et al.  Novel indenoisoquinolines NSC 725776 and NSC 724998 produce persistent topoisomerase I cleavage complexes and overcome multidrug resistance. , 2007, Cancer research.

[29]  Daniel A. Koster,et al.  Antitumour drugs impede DNA uncoiling by topoisomerase I , 2007, Nature.

[30]  Jérôme Kluza,et al.  Cancer cell mitochondria are direct proapoptotic targets for the marine antitumor drug lamellarin D. , 2006, Cancer research.

[31]  R. Millikan,et al.  Mitochondrial DNA G10398A polymorphism and invasive breast cancer in African-American women. , 2005, Cancer research.

[32]  Y. Pommier,et al.  Synthesis and mechanism of action studies of a series of norindenoisoquinoline topoisomerase I poisons reveal an inhibitor with a flipped orientation in the ternary DNA-enzyme-inhibitor complex as determined by X-ray crystallographic analysis. , 2005, Journal of medicinal chemistry.

[33]  Guido Davidzon,et al.  Mitochondrial DNA and disease , 2005, Annals of medicine.

[34]  John A. Hall,et al.  mtDNA mutations increase tumorigenicity in prostate cancer. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[35]  C. Bailly Lamellarins, from A to Z: a family of anticancer marine pyrrole alkaloids. , 2004, Current medicinal chemistry. Anti-cancer agents.

[36]  Christian Bailly,et al.  Lamellarin D: a novel potent inhibitor of topoisomerase I. , 2003, Cancer research.

[37]  D. Friedman,et al.  A truncated form of DNA topoisomerase IIbeta associates with the mtDNA genome in mammalian mitochondria. , 2003, European journal of biochemistry.

[38]  James C. Wang,et al.  Dual localization of human DNA topoisomerase IIIα to mitochondria and nucleus , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[39]  Y. Pommier,et al.  Human mitochondrial topoisomerase I , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[40]  V. Weissig,et al.  Mitochondrial DNA metabolism targeting drugs. , 2001, Advanced drug delivery reviews.

[41]  Keshav K. Singh,et al.  Mitochondrial DNA determines the cellular response to cancer therapeutic agents , 1999, Oncogene.

[42]  Y. Pommier,et al.  Poisoning of human DNA topoisomerase I by ecteinascidin 743, an anticancer drug that selectively alkylates DNA in the minor groove. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[43]  Y. Pommier,et al.  Induction of Reversible Complexes between Eukaryotic DNA Topoisomerase I and DNA-containing Oxidative Base Damages , 1999, The Journal of Biological Chemistry.

[44]  W G Hol,et al.  A model for the mechanism of human topoisomerase I. , 1998, Science.

[45]  E. Kraut,et al.  Analysis of topoisomerase I/DNA complexes in patients administered topotecan. , 1995, Cancer research.

[46]  Y. Pommier,et al.  Comparison of topoisomerase I inhibition, DNA damage, and cytotoxicity of camptothecin derivatives presently in clinical trials. , 1994, Journal of the National Cancer Institute.

[47]  T. Burke,et al.  The structural basis of camptothecin interactions with human serum albumin: impact on drug stability. , 1994, Journal of medicinal chemistry.

[48]  K. Kohn,et al.  Protein-linked DNA strand breaks induced in mammalian cells by camptothecin, an inhibitor of topoisomerase I. , 1989, Cancer research.

[49]  J. Wang,et al.  DNA topoisomerase-targeting antitumor drugs can be studied in yeast. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[50]  R. Hertzberg,et al.  Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. , 1985, The Journal of biological chemistry.

[51]  P. Slonimski,et al.  Mitochondrial genetics , 2004, Molecular and General Genetics MGG.

[52]  James C. Wang,et al.  Dual localization of human DNA topoisomerase IIIalpha to mitochondria and nucleus. , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[53]  D. A. Clayton,et al.  Replication and transcription of vertebrate mitochondrial DNA. , 1991, Annual review of cell biology.